Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Controlled-Release Formulations
- Controlled Release Formulations
- Controlled-Release Formulation
Sustained-Release Preparations- Sustained-Release Preparations
- Sustained-Release Preparation
- Extended Release Preparations
- Extended Release Preparation
- Slow Release Formulation
- Sustained Release Formulations
- Sustained Release Formulation
- Extended Release Formulations
- Extended Release Formulation
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in this website by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 2 | 8 | 10 |
| 2007 | 1 | 12 | 13 |
| 2008 | 0 | 14 | 14 |
| 2009 | 0 | 5 | 5 |
| 2010 | 1 | 6 | 7 |
| 2011 | 0 | 5 | 5 |
| 2012 | 1 | 4 | 5 |
| 2013 | 0 | 4 | 4 |
| 2014 | 1 | 8 | 9 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 5 | 6 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 5 | 5 |
| 2019 | 0 | 5 | 5 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles.
-
Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study. J Assoc Nurses AIDS Care. 2024 Sep-Oct 01; 35(5):437-449.
-
Randomized double-blind placebo-controlled study to evaluate the effect of long-acting mesalamine on postinfectious irritable bowel syndrome with diarrhea. Neurogastroenterol Motil. 2024 Oct; 36(10):e14889.
-
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024 May; 127:104390.
-
Reprogramming Megakaryocytes for Controlled Release of Platelet-like Particles Carrying a Single-Chain Thromboxane A2 Receptor-G-Protein Complex with Therapeutic Potential. Cells. 2023 12 06; 12(24).
-
Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):350-360.
-
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study. J Child Adolesc Psychopharmacol. 2023 03; 33(2):51-58.
-
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.
-
A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2021 11; 31(9):597-609.
-
Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior. Biomed Res Int. 2021; 2021:3849093.
-
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Invest New Drugs. 2021 08; 39(4):1047-1056.